When you are weighing a non-surgical option for persistent back pain, percentages alone are not enough. You want to know whether reported improvements include measurable changes on imaging, better function, and experiences from appropriately screened patients.

For Chicago patients researching the technology, the most useful starting point is the quality of the published evidence rather than an isolated testimonial. You can review how the DRX9000 technology works, then examine what clinical trials and imaging studies actually measured.

What the Published Clinical Trials Show About DRX9000 Outcomes

Published evidence suggests that DRX9000 treatment can improve pain and function for some patients with lumbar disc herniation. But the studies do not establish a guaranteed result for every patient. The most useful data come from a single-blind randomized-controlled trial and a separate case series. Together, they offer measurable clinical findings while also showing why patient selection and careful interpretation matter.

What the randomized-controlled trial measured

The randomized trial published in Experimental and Therapeutic Medicine included 48 patients with low back pain associated with lumbar disc herniation. Participants were assigned to either conventional motorized traction or non-surgical spinal decompression delivered with a DRX9000 device. Each group completed 20 sessions over six weeks.

Researchers evaluated pain with the Visual Analog Scale (VAS), disability with the Oswestry Disability Index (ODI), and depressive symptoms with the Beck Depression Inventory (BDI). After treatment, both groups showed statistically significant declines in all three measures, with p<0.001. The study therefore supports meaningful short-term improvement across pain, function, and mood measures, rather than relying only on anecdotal reports. Read the full single-blind randomized-controlled trial for its methods and statistical results.

What the DRX9000 case series found

A Parker University case series examined 13 patients with MRI-confirmed lumbar intervertebral disc lesions. The patients received 20 DRX9000 treatments, and the researchers reported statistically significant improvement, with p<0.001, in three outcome categories: pain improved by 80%, disability by 50%, and subjective recovery by 75%.

These percentages describe changes observed within a small clinical group, not a promise that every patient will experience the same degree of relief. The published DRX9000 case series also reported imaging findings, which are addressed separately when reviewing structural outcomes. For additional context, see our overview of the clinical evidence for non-surgical decompression.

How to interpret the evidence responsibly

The randomized design strengthens the first study, but its sample was still relatively small and its follow-up focused on short-term results. The case series provides useful clinical and imaging observations, yet it had only 13 participants and did not include a randomized comparison group. These limitations mean the findings should guide informed discussion, not replace an individual examination.

DRX Chicago uses computer-controlled decompression intended to reduce intradiscal pressure, with reported treatment pressures in the range of -100 to -200 mm Hg. A comprehensive evaluation is still necessary to determine whether the treatment is appropriate, what condition is being addressed, and whether other medical care is needed.

How DRX9000 Clinical Results Translate into Success Rates

DRX Chicago reports clinical success rates of 76% to 88% for qualified candidates who follow the full treatment protocol. That range is meaningful, but it should not be read as a promise that every person with back pain will improve. The evaluation that comes before treatment helps determine whether spinal decompression is appropriate and whether the available clinical data reasonably applies to a patient’s condition.

In the published case-series data, patients experienced an average pain reduction of 80%. The study described the overall clinical outcomes as good, but pain is only one part of recovery. A meaningful result also includes improved function, such as greater mobility and a better ability to return to normal daily activities. Review the published clinical data for the study context and limitations.

• 76% to 88%: clinical success reported for qualified candidates following the full protocol.
• 80%: average pain reduction reported in the clinical case-series data.
• Two dimensions of success: reduced pain and measurable improvement in daily function.

Why the word “qualified” matters

Qualified does not mean simply having a diagnosis that appears on a treatment list. A comprehensive evaluation reviews symptoms, medical history, imaging, and potential contraindications. Screening may exclude people with conditions such as pregnancy, severe osteoporosis, spinal fractures, tumors, infections, or surgical hardware at the treatment level. That patient selection is one reason a published success rate is not 100%, and it is also why a consultation is necessary before discussing candidacy.

Adherence affects the result

Following the prescribed schedule matters as much as selecting an appropriate candidate. DRX Chicago’s protocol commonly involves a complete series of sessions, and the clinical data associates attendance and adherence with higher success rates. Stopping early or missing sessions can make it harder to evaluate the full effect of treatment.

For readers comparing outcomes across conditions, DRX Chicago also provides an overview of DRX9000 therapy success rates and the spinal problems the program may address. The next step is not assuming a statistic applies to you, but determining whether your diagnosis, imaging, and health history fit the population represented by the evidence.

MRI Evidence: Documented Disc Height Increases After Treatment

MRI findings provide a more objective view of some DRX Chicago patients’ progress. In a Parker University case series. Post-treatment imaging showed disc height increases of 1.0 to 1.6 mm and increases of 1.5 to 2.1 mm in the canal’s anterior-posterior dimension. These measurements do not guarantee a particular result, but they document physical changes beyond a patient’s subjective report.

What these MRI changes can mean for patients

Disc height is the space between adjacent vertebrae where the intervertebral disc sits. When that space increases after treatment, it may reflect improved disc hydration and reduced compression within the disc. In the Parker University case series, 13 patients received 20 DRX9000 treatments after MRI confirmed their disc lesions. The researchers reported statistically significant improvements in pain, disability, and subjective recovery, alongside the imaging changes.

The proposed mechanism is controlled rather than forceful stretching. Computer-controlled logarithmic decompression can create approximately -100 to -200 mm Hg of negative intradiscal pressure. Research describes this pressure change as a mechanism that may encourage fluid movement, disc hydration, and retraction of herniated or bulging material. Read the published discussion of non-surgical spinal decompression and its proposed mechanism for the underlying research context.

For an individual patient, MRI comparisons must be interpreted alongside symptoms, physical findings, and functional changes. A larger disc space or smaller herniation on imaging is meaningful, but it does not replace a clinical evaluation or establish that decompression is appropriate for everyone.

What the Yochum case report documented

A separate Yochum case report followed a patient with an L5/S1 extruded disc herniation that displaced the left S1 nerve root. After treatment and follow-up care, the report described a 100% reduction in symptoms. Repeat weight-bearing MRI performed approximately 7.5 months after treatment showed complete reduction of the previously visualized herniation.

This is an encouraging example of symptom and imaging change occurring together. But it remains a single case report, not proof that every extruded herniation will respond the same way. The full case details are available in the Yochum DRX9000 case report. A qualified provider should review your history and imaging before discussing whether this approach fits your condition.

Patient Satisfaction vs. Outcome: What the Numbers Mean

Patient satisfaction measures how people feel about their experience and progress, while a clinical outcome uses observable measures such as pain, function, or imaging. Both perspectives matter when evaluating DRX9000 care, but they answer different questions. Satisfaction can reflect meaningful improvements in daily life, while an outcome assessment asks whether a defined clinical change occurred.

DRX Chicago reports a 95% patient satisfaction rate based on post-treatment surveys across more than 14,500 DRX9000 treatments. The practice also has more than 290 five-star Google reviews with a 4.9 out of 5.0 average. These figures provide useful context about how patients describe their care, communication, and experience, but reviews and surveys are not substitutes for controlled clinical measurements.

Why satisfaction and success rates are not identical

A patient may feel satisfied because treatment helped them avoid surgery, continue most daily routines without a prolonged recovery period, or receive attentive guidance throughout the process. Those benefits can be important even when pain relief is incomplete or imaging shows only a partial change. Conversely, an objective improvement does not guarantee that every patient will feel the result met their personal expectations.

That is why a reported satisfaction rate can be higher than clinical success-rate ranges. A success assessment typically considers defined changes in pain and function among qualified candidates, while satisfaction includes the broader patient experience. For background on the treatment mechanism and what the device is designed to do, see how the DRX9000 works.

What these numbers cannot promise

Neither satisfaction data nor clinical results guarantee a particular outcome. Candidacy, diagnosis, adherence to the recommended plan, and individual health factors all influence response. DRX Chicago’s clinical team, led by Dr. Jason Ingham, DC, CCSP, and Dr. Erin Schey, DC, uses an evaluation to determine whether the approach is appropriate. The most responsible interpretation is balanced: patient-reported experience and objective clinical change can support a decision, but neither should replace an individualized assessment.

Who Gets the Best Results from DRX9000 Treatment

DRX9000 treatment is most appropriate for carefully screened candidates with conditions such as herniated or bulging discs. Sciatica, degenerative disc disease, or spinal stenosis, particularly when conservative care has not provided enough relief. Results are not guaranteed, and candidacy depends on the findings of an examination and imaging review.

Conditions with the strongest evidence base

Patients are generally considered when symptoms can be connected to a specific spinal level and the clinical picture supports decompression. A history of unsuccessful physical therapy or other conservative care may make an evaluation reasonable, but it does not replace a complete assessment. DRX Chicago has performed more than 14,500 DRX9000 treatments, with care led by Dr. Jason Ingham, DC, CCSP, and Dr. Erin Schey, DC.

The usual protocol involves 20 to 28 sessions over four to seven weeks. Frequency typically begins with daily visits, then tapers to three sessions per week and eventually two sessions per week. Completing the prescribed schedule matters because the treatment plan is designed as a graduated program rather than a single procedure.

If you are comparing approaches, you can compare DRX9000 against other non-surgical options before deciding whether to request an evaluation.

The candidacy evaluation

A candidacy visit combines a clinical examination with a review of available MRI or other imaging. This helps identify the symptomatic level and determine whether the condition is suitable for targeted decompression. The evaluation also looks for circumstances in which DRX9000 should not be used, including pregnancy. Severe osteoporosis, spinal fractures, tumors, infections, ankylosing spondylitis, or prior surgery at the treatment level.

DRX9000 is non-invasive and typically involves little to no recovery time, but that does not make it appropriate for every back problem. Surgery may be medically necessary for some conditions and should not be delayed when a physician recommends it. A comparison can clarify the differences without treating any option as universally best. The table below summarizes the main contrasts:

How DRX9000 compares with surgery and traditional traction

Approach	Invasiveness and downtime	Typical cost range	When it may fit
DRX9000 decompression	Non-invasive. Usually little to no recovery time between sessions.	$2,500-$4,500 for a treatment program.	Screened candidates seeking a non-surgical option.
Spinal surgery	Invasive. Recovery and activity restrictions vary by procedure.	$50,000-$150,000.	Conditions requiring medically necessary surgical care.
Traditional traction	Non-invasive. Timing and downtime depend on the treatment plan.	Varies by provider and coverage.	Selected cases where traction is clinically appropriate.

Program ranges are not promises of exact pricing, and insurance coverage varies. A free consultation can help determine whether the findings, diagnosis, and treatment goals align with DRX9000 care.

Frequently Asked Questions

What clinical success rate can qualified patients expect?

Published clinical evidence and customer-verified treatment data place clinical success for qualified candidates in the 76% to 88% range. Results vary by diagnosis, symptom duration, overall health, and adherence to the complete protocol. The range is not a guarantee for any individual, and the published clinical study describes the full protocol and its limitations.

Can MRI scans show measurable changes after treatment?

Yes. Published imaging research has documented MRI-verified increases in disc height of approximately 1.0 to 1.6 mm after non-surgical spinal decompression. Imaging findings are one part of the evaluation and should be considered alongside pain, function, and neurological symptoms. (MRI research)

How much pain reduction is typically reported?

Patients in the cited case series experienced an average pain reduction of about 80%. That figure describes a study-group average, not a promised outcome. And meaningful improvement depends on whether a patient is an appropriate candidate and completes the recommended care plan. (Case series)

How many DRX9000 sessions are usually needed?

The standard DRX9000 protocol generally includes 20 to 28 sessions over 4 to 7 weeks. The schedule may begin with more frequent visits and taper as symptoms and clinical findings are reassessed. (DRX Chicago protocol information)

Who should be evaluated before considering treatment?

People with conditions such as herniated or bulging discs, sciatica, degenerative disc disease, or spinal stenosis may be candidates after a comprehensive evaluation. Screening matters because pregnancy, severe osteoporosis, spinal fractures, tumors, infections, surgical hardware, and ankylosing spondylitis may make treatment inappropriate. A full evaluation is always required, and DRX Chicago candidacy information explains the screening process.

Schedule Your Free Consultation

DRX Chicago can review your symptoms, health history, and goals to help determine whether a comprehensive evaluation for DRX9000 treatment is appropriate for you. A personalized conversation gives you a clearer understanding of candidacy and possible next steps without promising results in advance. To discuss your situation, schedule your free consultation through our patient survey, or call our office directly at (773) 868-0347.